H2020-JTI-IMI2-2019-18-two-stage
H2020-JTI-IMI2-2019-18-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 6
- EU contribution (sum)
- €74,859,537
- Portal deadline
- —
Leading topic in historical projects: IMI2-2019-18-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- EORTC1 coordinated
- MEDIZINISCHE UNIVERSITAET WIEN1 coordinated
- RADBOUDUMC1 coordinated
- USFD1 coordinated
- KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT1 coordinated
- UNIVERSITY OF OSLO1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- ROCHE3 topic projects
- NOVARTIS3 topic projects
- PFIZER3 topic projects
- i-HD3 topic projects
- ASTRAZENECA AB2 topic projects
- BAYER AKTIENGESELLSCHAFT2 topic projects
- ELI LILLY AND COMPANY LTD2 topic projects
- EUROPEAN PATIENTS FORUM2 topic projects
- JANSSEN PHARMACEUTICA NV2 topic projects
- KU Leuven2 topic projects
- SARD2 topic projects
- UCB2 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- 4 shared
- 4 shared
- BAYER AKTIENGESELLSCHAFT · PFIZER4 shared
DE ↔ UK
- 3 shared
- 3 shared
- 3 shared
- 3 shared
- 3 shared
- 3 shared
- BAYER AKTIENGESELLSCHAFT · NOVARTIS3 shared
DE ↔ CH
- 3 shared
- JANSSEN PHARMACEUTICA NV · PFIZER3 shared
BE ↔ UK
- JANSSEN PHARMACEUTICA NV · NOVARTIS3 shared
BE ↔ CH
- 3 shared
- JANSSEN PHARMACEUTICA NV · IRIS2 shared
BE ↔ FR
- 2 shared
- JANSSEN PHARMACEUTICA NV · SARD2 shared
BE ↔ FR
- JANSSEN PHARMACEUTICA NV · Novo Nordisk2 shared
BE ↔ DK
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 38.33
- Median orgs / project
- 35
- Min / max orgs
- 29 – 53
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- Germany29
- Belgium27
- Netherlands24
- United Kingdom23
- Spain17
- France17
- Switzerland15
- Sweden12
- United States9
- Norway9
- Denmark8
- Italy8
- Austria7
- Finland5
- Ireland5
- Portugal4
- Canada2
- Hungary2
Organization types
- company35 orgs · 63 rows
- university53 orgs · 61 rows
- research_institute33 orgs · 38 rows
- sme32 orgs · 32 rows
- other19 orgs · 20 rows
- public_body15 orgs · 16 rows
Topics in funded projects
- IMI2-2019-18-01IMI2-2019-18-01· 1 projects
- IMI2-2019-18-02IMI2-2019-18-02· 1 projects
- IMI2-2019-18-03IMI2-2019-18-03· 1 projects
- IMI2-2019-18-04IMI2-2019-18-04· 1 projects
- IMI2-2019-18-05IMI2-2019-18-05· 1 projects
- IMI2-2019-18-06IMI2-2019-18-06· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| BIGPICTURE Central Repository for Digital Pathology | H2020 | €32,319,825 |
| ARDAT Accelerating Research & Development for Advanced Therapies | H2020 | €11,773,000 |
| H2O H2O Health Outcomes Observatory | H2020 | €10,476,687 |
| Gravitate-Health Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment | H2020 | €9,280,000 |
| T2EVOLVE Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy | H2020 | €8,728,185 |
| SISAQOL-IMI Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials | H2020 | €2,281,840 |